Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Technologies Sues Molecular Devices for Patent Infringement

NEW YORK, May 17 - Caliper Technologies is suing Molecular Devices for patent infringement, according to securities documents filed by MDC on Wednesday.


The lawsuit, filed in the US District Court for the Northern District of California on April 16, alleges that MDC's kinase-assay products violate Caliper's US patents. 


Caliper seeks damages for past sales of IMAP products and an injunction against future sales.


Molecular Devices filed an answer and counter-claim on May 8 denying the allegations, making a counter-claim for declaratory relief and alleging that the Caliper patent is invalid.


Both companies have developed non-radioactive systems for high-throughput kinase assays.


MDC's IMAP products work through the binding of trivalent metal ions to phosphate groups to create changes in fluorescence polarization.


The Caliper patent in question covers a range of assays in which the reaction product is bound to a polyionic component, and then detected through conventional means.


MDC says that its IMAP products account for less than 1 percent of company revenue.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.